knowledge -WSS

knowledge

author：entertainment 2025-10-02 19:15:29 - browse：569

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Medicare Advantage proposed rates disappoint insurers

entertainment

WSS

KalVista pill reduced swelling 'attacks' caused by genetic disease

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

Eisai exec who led development of Alzheimer’s drug to retire

The U.S. needs a new definition of substance use “recovery”

Medicare wants to send $9 billion to 340B hospitals

Robert F. Kennedy is pitching centrism on health, even on abortion

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medical records are filled with copy

Parents surprise family after baby discharged from NICU after 170 days

In Memoriam: Notable people who died in 2023

Recent heat wave in the Mediterranean caused by climate change: Study

Activists slam private health insurers over coverage restrictions

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Moonlake's readout produced a cash windfall. Risks remain

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

At least 13 dead in Texas as scorching temps continue

PhRMA lawsuit over Medicare drug price negotiation tossed

entertainment

ACA's risk program benefits Blue Cross Blue Shield insurers

How digital tools helped lower hypertension in marginalized patients

A disappointing year of Humira biosimilars

KalVista pill reduced swelling 'attacks' caused by genetic disease

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Biden report: The neurospychology of memory and aging

entertainment

entertainment

entertainment

hotspot